Lmcg Investments LLC Lowers Stock Holdings in Inspire Medical Systems, Inc. $INSP

Lmcg Investments LLC trimmed its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 7.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,659 shares of the company’s stock after selling 2,181 shares during the quarter. Lmcg Investments LLC’s holdings in Inspire Medical Systems were worth $3,330,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS lifted its holdings in shares of Inspire Medical Systems by 10.5% in the second quarter. KLP Kapitalforvaltning AS now owns 6,300 shares of the company’s stock worth $818,000 after buying an additional 600 shares in the last quarter. 111 Capital purchased a new stake in shares of Inspire Medical Systems in the second quarter worth about $300,000. Janney Montgomery Scott LLC lifted its holdings in shares of Inspire Medical Systems by 22.7% in the second quarter. Janney Montgomery Scott LLC now owns 5,316 shares of the company’s stock worth $690,000 after buying an additional 984 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in shares of Inspire Medical Systems in the second quarter worth about $338,000. Finally, State of Alaska Department of Revenue lifted its holdings in shares of Inspire Medical Systems by 6.8% in the second quarter. State of Alaska Department of Revenue now owns 17,556 shares of the company’s stock worth $2,277,000 after buying an additional 1,116 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Price Performance

Shares of NYSE INSP opened at $75.23 on Friday. Inspire Medical Systems, Inc. has a one year low of $70.77 and a one year high of $216.01. The firm’s 50 day simple moving average is $84.07 and its two-hundred day simple moving average is $121.81. The stock has a market capitalization of $2.22 billion, a P/E ratio of 43.49, a PEG ratio of 2.50 and a beta of 1.16.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The business had revenue of $217.09 million for the quarter, compared to analysts’ expectations of $214.50 million. During the same period last year, the business earned $0.32 earnings per share. The business’s quarterly revenue was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems declared that its Board of Directors has initiated a stock repurchase program on Monday, August 11th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 8.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares in the company, valued at $4,190,129.13. This trade represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, July 26th. Wells Fargo & Company lowered their target price on shares of Inspire Medical Systems from $174.00 to $101.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $150.00 target price on shares of Inspire Medical Systems in a research note on Friday. Evercore ISI lowered their target price on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, UBS Group set a $89.00 target price on shares of Inspire Medical Systems and gave the company a “neutral” rating in a research note on Monday, September 22nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $150.50.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.